Title
Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: Together we are stronger
Date Issued
01 January 2018
Access level
open access
Resource Type
journal article
Author(s)
Handy C.E.
Pinto X.
Blaha M.J.
Blumenthal R.S.
Michos E.D.
Lima J.A.C.
Guallar E.
Ryu S.
Cho J.
Kaye J.A.
Comin-Colet J.
Corbella X.
Cainzos-Achirica M.
Albert Einstein College of Medicine
Publisher(s)
Lippincott Williams and Wilkins
Abstract
Cardiovascular disease (CVD) and cancer continue to be the 2 leading causes of death in developed countries despite significant improvements in the prevention, screening, and treatment of both diseases. They remain significant public health problems, growing in importance globally. Despite this threat, the fields of cardiology and oncology have been relatively disconnected. With many shared modifiable risk factors, cancer and CVD often coexist in the same individuals; those diagnosed with lung cancer, breast cancer, and colon cancer are at higher risk of CVD, and those with CVD are at higher risk of developing many types of common cancers. Screening paradigms have been established in parallel, but there are opportunities for combined risk assessments for cancer and CVD risk. Joining forces for combined cardiovascular and hemato-oncological preventive and research efforts will likely have synergistic, worldwide public health benefits.
Start page
727
End page
734
Volume
138
Issue
7
Language
English
OCDE Knowledge area
Sistema cardiaco, Sistema cardiovascular Oncología
Scopus EID
2-s2.0-85055647713
PubMed ID
Source
Circulation
ISSN of the container
00097322
Sponsor(s)
Dr Handy received research support from the Conquer Cancer Foundation/ Bristol-Meyers Squibb. Dr Kaye is a full-time employee of Research Triangle Institute Health Solutions, an independent nonprofit research organization which has received funding from Novartis and other pharmaceutical companies. Dr Blaha has served on an Advisory Board for Novartis. Dr Cainzos-Achirica collaborates with Research Triangle Institute Health Solutions, an independent nonprofit research organization that has received funding from Novartis and other pharmaceutical companies. The other authors report no conflicts.
Sources of information: Directorio de Producción Científica Scopus